Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis
Andrew D Goodman1, Theodore R Brown1, Randall T Schapiro1
1Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA (ADG); Evergreen Hospital Medical Center, Kirkland, WA, USA (TRB); Minneapolis Clinic of Neurology, Minneapolis, MN, USA (RTS); and Acorda Therapeutics, Inc., Ardsley, NY, USA (MK, RC, ARB).
Background:
Two phase 3 clinical trials demonstrated that dalfampridine extended-release 10-mg tablets (D-ER), twice daily, significantly improved walking relative to placebo in patients with multiple sclerosis (MS). The objective of this study was to evaluate the efficacy and safety of D-ER in patients with MS using pooled data from the two phase 3 trials.
Methods:
Data were pooled from the two trials, and D-ER was compared with placebo for timed-walk responder rate, changes in walking speed, and the 12-item Multiple Sclerosis Walking Scale (MSWS-12). Response rates were evaluated with respect to demographic and clinical characteristics.
Results:
D-ER had a significantly higher proportion of timed-walk responders relative to placebo (37.6% vs. 8.9%; P < .0001). The responder rate was independent of age, gender, race, body-mass index, type of MS, duration of MS, baseline Expanded Disability Status Scale score, baseline walking speed, and concomitant use of immunomodulatory therapies. Significant improvements were observed in walking speed and in MSWS-12 score for the pooled D-ER group compared with placebo. The safety profile was consistent with the individual studies; no new safety or tolerability concerns were identified.
Conclusions:
D-ER demonstrated efficacy for the improvement of walking in patients with MS; response was independent of demographic and clinical characteristics.
